TICKERNOMICS Sign up
Last Update: 2024-03-28 02:12:38
MARINUS PHARMACEUTICALS INC. ( MRNS ) https://marinuspharma.com
8.79USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
MRNS
40.87%
SPY
32.74%
-39.42%
MRNS
SPY
92.93%
-47.43%
MRNS
SPY
224.41%
MRNS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
487.38
512.89
0.57
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-3.64
15.74
29.07
-26.85
0.00
-4.11
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-431.26
93.80
-401.14
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.4547
-81.13
-75.59
1.39
Other Earnings and Cash Flow Stats:
MARINUS PHARMACEUTICALS INC. ( MRNS ) Net Income TTM ($MM) is -28.57
MARINUS PHARMACEUTICALS INC. ( MRNS ) Operating Income TTM ($MM) is -16.14
MARINUS PHARMACEUTICALS INC. ( MRNS ) Owners' Earnings Annual ($MM) is -114.68
MARINUS PHARMACEUTICALS INC. ( MRNS ) Current Price to Owners' Earnings ratio is -4.18
MARINUS PHARMACEUTICALS INC. ( MRNS ) EBITDA TTM ($MM) is -11.09
MARINUS PHARMACEUTICALS INC. ( MRNS ) EBITDA Margin is -401.14%
Capital Allocation:
MARINUS PHARMACEUTICALS INC. ( MRNS ) has paid 0.00 dividends per share and bought back -15.505522 million shares in the past 12 months
MARINUS PHARMACEUTICALS INC. ( MRNS ) has reduced its debt by 14.25 million USD in the last 12 months
Capital Structure:
MARINUS PHARMACEUTICALS INC. ( MRNS ) Interest-bearing Debt ($MM) as of last quarter is 61
MARINUS PHARMACEUTICALS INC. ( MRNS ) Annual Working Capital Investments ($MM) are -11
MARINUS PHARMACEUTICALS INC. ( MRNS ) Book Value ($MM) as of last quarter is 16
MARINUS PHARMACEUTICALS INC. ( MRNS ) Debt/Capital as of last quarter is 366%
Other Balance Sheet Stats:
MARINUS PHARMACEUTICALS INC. ( MRNS ) has 120 million in cash on hand as of last quarter
MARINUS PHARMACEUTICALS INC. ( MRNS ) has 40 million of liabilities due within 12 months, and long term debt 72 as of last quarter
MARINUS PHARMACEUTICALS INC. ( MRNS ) has 54 common shares outstanding as of last quarter
MARINUS PHARMACEUTICALS INC. ( MRNS ) has 4 million USD of preferred stock value
Academic Scores:
MARINUS PHARMACEUTICALS INC. ( MRNS ) Altman Z-Score is -4.20 as of last quarter
MARINUS PHARMACEUTICALS INC. ( MRNS ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
MARINUS PHARMACEUTICALS INC. ( MRNS ) largest shareholder is owning shares at 0.00 ($MM) value
Steven Pfanstiel(an insider) Sold 2790 shares of MARINUS PHARMACEUTICALS INC. ( MRNS ) for the amount of $26616.60 on 2023-08-07
0.78% of MARINUS PHARMACEUTICALS INC. ( MRNS ) is held by insiders, and 86.41% is held by institutions
MARINUS PHARMACEUTICALS INC. ( MRNS ) went public on 2014-07-31
Other MARINUS PHARMACEUTICALS INC. ( MRNS ) financial metrics:
FCF:-119.74
Unlevered Free Cash Flow:-97.49
EPS:-2.42
Operating Margin:-431.26
Gross Profit Margin:93.80
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-786.69
Beta:1.39
Buffet's Owners Earnings:-114.68
Price to Owner's Earnings:-4.18
About MARINUS PHARMACEUTICALS INC. ( MRNS ) :
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.